ReviewCurrent oncology reports2023
Extramammary Paget Disease: a Therapeutic Challenge, for a Rare Entity.
Review in Current oncology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 16 citations in OpenAlex.
- Trial
- Dramatic response to trastuzumab-deruxtecan in metastatic HER2-overexpressing vulvar extramammary Paget's disease: A case report.Gynecologic oncology reports · 2026Article
- Concurrent chemoradiotherapy for metastatic vulvar extramammary Paget's disease involving supraclavicular nodes: a case report.Radiation oncology journal · 2026Article
- Treatment Strategies for Extramammary Paget Disease: A Narrative Review of Current Status and Future Directions.Cancers · 2026Review
- Photodynamic technology for delineating surgical margins in recurrent extramammary Paget's disease: a case report.Frontiers in medicine · 2026Article
- Case Report: staged electron beam radiotherapy for inoperable primary ectopic abdominal extramammary Paget disease.Frontiers in oncology · 2026Article
- Therapeutic Algorithm for Extramammary Paget Disease: Experience in a Dermatology Referral Center in Western Mexico.Cureus · 2026Article
- Rare Localization of Extramammary Paget's Disease in the Axilla: A Case Report and Literature Review.Journal of clinical medicine · 2025Article
- Assessing mortality risk and causes in extramammary Paget's disease: insights from a population-based study.Translational cancer research · 2025Article
- Genomics of cervical, vulvar and vaginal cancers and the potential of precision medicine.Therapeutic advances in medical oncology · 2025Review
- Repair of Scrotal Wounds after Extensive Excision of Extramammary Paget Disease with Thick Split-thickness Skin Graft.Plastic and reconstructive surgery. Global open · 2024Article
- Challenges in treating coexisting scrotal apocrine carcinoma and gastric cancer: insights from an elderly patient: a case report and literature review.BMC geriatrics · 2024Review
- Prognostic and Predictive Roles of HER2 Status in Non-Breast and Non-Gastroesophageal Carcinomas.Cancers · 2024Review
- Re: Erythematous Plaque in the Left Axillary Region: A diagnostic challenge where dermoscopy can help.Sultan Qaboos University medical journal · 2024Article
- The elusive extremities: a case of extramammary Paget disease.BMJ case reports · 2024Article
- Case report: Disitamab vedotin combined with immunotherapy demonstrated excellent efficacy in scrotal Paget's disease with Her-2 overexpression.Frontiers in immunology · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewExtramammary Paget disease (EMPD) is a rare entity which is more frequently localized at the vulva, though it only accounts for 1-2% of vulvar neoplasms. It is a primary cutaneous adenocarcinoma whose cell of origin is still a matter of controversy: it can either arise from apocrine/eccrine glands or from stem cells. The diagnosis demands a biopsy and entails a histopathological analysis by which cells show similar characteristics as breast Paget disease. RECENT
findingsTreatment approach can entail surgery, radiotherapy, photodynamic therapy, systemic chemotherapy, and topical chemotherapy. For metastatic disease, many different chemotherapy regimens have been explored and even targeted therapy can play an important role in this disease. Since almost 30-40% of patients overexpress HER-2, trastuzumab and anti-HER-2 therapies can be employed in this setting. Due to its low incidence, there is almost no specific evidence on therapeutic interventions for this disease. Thus, there is a neat unmet need for molecular characterization of EMPD and diagnostic tools that allow clinicians to guide treatment both in the early and in the advanced disease settings. In this review, we aim to summarize available evidence about diagnosis and treatment of EMPD, both localized and metastatic, and to provide a comprehensive analysis that may help clinicians for therapeutic decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.